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Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tb), continues to be
one of the most prevalent infectious diseases in the world. There is an upward trend
in occurrence due to emerging multidrug resistant strains and an increasingly larger
proportion of immunocompromised patient populations as a result of the acquired
immunodeficiency syndrome pandemic. The complex and often deadly combination of
multidrug resistant M. tb (MDR-M. tb) along with human immunodeficiency virus (HIV)
puts a significant number of people at high risk for pulmonary and extra-pulmonary TB
without sufficient therapeutic options available. Natural killer (NK) cells and macrophages
are major components of the body’s innate immune system, contributing significantly to
the body’s ability to synergistically inhibit the growth of M. tb in immune compromised
individuals lacking a sufficient T cell response. Direct mechanisms of control are largely
through the secretory products perforin, granulysin, and granzymes, as well as multiple
membrane-bound death receptors that facilitate target directed lysis. NK cells also have a
role in indirectly stimulating an immune response through activation of macrophages and
monocytes with multiple signaling pathways, including both reactive oxygen species and
reactive nitrogen species. Glutathione (GSH) has been shown to play a part in inhibiting
the growth of intracellular M. tb through bacteriostatic mechanisms. Enhancing cellular
GSH through several cytokines and N-acetyl cysteine has been shown to increase these
effects, at least in part, through their action on NK cells. Taken together, there is substantial
evidence for a mechanistic correlation between NK cell activity and functionality in
combating M. tb in HIV infection mediated through adequate GSH production and use.
Keywords: natural killer cells, macrophages, Mycobacterium tuberculosis, HIV infections, AIDS-related oppor-
tunistic infections, glutathione, innate immunity
Epidemiology of Tuberculosis, Drug Resistance, and
HIV Co-Infection
Mycobacterium tuberculosis (M. tb), the causative agent for tuberculosis (TB), spreads from person
to person through airborne transmission. The spread of MDR-M. tb and the increased number
of immunocompromised individuals due to the acquired immunodeficiency syndrome (AIDS)
pandemic have led to an increasing incidence of M. tb infection (1–4). TB remains an important
public health problem with 9 million new cases and 1.5 million deaths in 2013 (5). Of these deaths,
0.36 million people were also co-infected with human immunodeficiency virus (HIV) (6).
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Drug resistance poses a significant challenge to TB control
and treatment. MDR-M. tb and extensively drug-resistant TB
(XDR-M. tb) require longer treatment time, and more expensive
second-line anti-TB drugs with additional side effects. Addition-
ally, cases of “totally drug-resistant TB” (TDR-TB) have been
reported globally (7–9).
Patients with AIDS due to HIV infection are susceptible to
opportunistic pathogens, with TB being the most common and
perhaps the leading cause of death in these patients (1, 2, 5). There
is a dangerous relationship between TB and HIV co-infection,
with HIV increasing the likelihood of TB infection, and TB wors-
ening the clinical course of HIV infection (2). In immunocompro-
mised individuals with impaired adaptive immunity, natural killer
(NK) cells could serve as the major immune cells contributing to
innate defense against bacterial infection (4, 10).
M. tb Infection and Host Immune
Responses in the Lungs
Initial M. tb infection occurs in the lungs, where invading
Mycobacterium are phagocytosed by alveolar macrophages. Bind-
ing of toll-like receptors (TLRs) triggers the release of inflam-
matory mediators of the innate immune response. Neutrophils,
NK cells, and eventually T-cells respond to these signals and
are thought to contribute to early defenses against M. tb infec-
tion (11). These early responses frequently prove unsuccessful
in combating the initial infection. In such cases, the infection
spreads via macrophages and dendritic cells (DCs) to the drain-
ing lymph nodes, through the bloodstream to various organs.
However, the initial infection only progresses to overt disease in
a small number of cases. In most immune competent patients,
granulomas form to contain the infectingMycobacterium, driven
by proliferation of CD4 and CD8 T-cell lineages (11). Within
the granulomas M. tb cells are contained without being com-
pletely eradicated, leading to a subclinical persistent infection,
termed latent TB infection (LTBI). Immunodeficiency due toHIV
infection represents the greatest recognized threat to successful
containment of LTBI (1). Therefore, both innate and adaptive
immune responses are extremely important for in combating M.
tb infection (4, 12, 13). Activated alveolar macrophages provide
the first-line defense againstM. tb infection by phagocytosing the
bacteria and mounting appropriate effector mechanisms within
the intracellular environment, thereby limiting the growth of the
pathogen and preventing overt disease (10, 13). AlthoughNK cells
are not phagocytic, these cells can still play a pivotal role in innate
defense againstM. tb infection by various mechanisms described
in this review (2, 10, 14–27).
Natural Killer Cells and
Cytotoxic Mechanisms
Natural killer cells are granular lymphocytes that expressCD16, an
Fc receptor, and CD56, a neural cell adhesion molecule (NCAM)
(28). NK cells carry out non-MHC-restricted cytotoxicity against
pathogens alongwith host cells that have lowered or absent expres-
sion of MHC class I molecules (29, 30). The cytolytic functions
of NK cells are regulated by the engagement of both activating
and inhibitory cell-surface receptors (30). MHC class I molecules
are expressed by nucleated cells and engage inhibitory NK cell
receptors, such as killer cell Ig-like receptors (KIRs), leukocyte
Ig-like receptor (LIR), and CD94/NKG2 receptors, to prevent
cytolysis (31, 32). CD94 is a C-type lectin protein, which can not
only dimerize with NKG2 family proteins to create an inhibitory
receptor but can also dimerize with NKG2C, -E, and -H and func-
tion as an activating receptor. Most of the CD94/NKG2 receptors
are heterodimers, which bind to the non-classical class I molecule
HLA-E (31, 32). NK cells bear a variety of activating receptors,
including NKp30, NKp44, and NKp46, the surface expression of
which is associated with increased lysis of target cells (6, 33, 34).
Cytokines, such as IL-2 and IL-12, have both been shown to
increase and activate NK cell activity. IL-2 enhances the lytic
activity ofNK cells, commonly referred to as lymphocyte activated
killer (LAK) activity (4). The cytolytic activity of NK cells has also
been demonstrated with IL-2 treatment on macrophages infected
with Legionella, Shigella, and Rickettsia (35). IL-12 is a power-
ful NK cell stimulatory factor secreted by macrophages, neu-
trophils, and DCs after exposure to pathogens or cytokines(22).
IL-12 signaling increases NK cell function and promotes synthesis
and secretion of interferon gamma (IFN-γ). NK cells activated
by IL-12 have been shown to inhibit the growth of M. tb and
Mycobacterium avium (19, 22).
Two suggested mechanisms help explain the involvement of
NK cells in the defense against microbes: direct and indirect. NK
cells bind to microorganisms and provide direct cytotoxicity via
secreted bactericidal molecules (19). The expression of surface
ligands on NK cells provides the capability of killing pathogens
and target cells by inducing apoptosis (36–40). Through secreted
cytokines, such as IFN-γ and tumor necrosis factor-alpha (TNF-
α), NK cells can activate macrophages and other members of the
immune system, resulting in the indirect killing of pathogens.
Direct Mechanisms of NK Cell-Mediated
Control of Infection
Natural killer cells have several direct mechanisms of cytotoxi-
city, including cytoplasmic granules containing perforin, gran-
ulysin, and granzymes, as well as several death receptors that
can initiate apoptosis (Figures 1 and 4). Perforin belongs to
the membrane-attack-complex protein family, and inserts into
target cellular membranes to function as a pore similar to the
c5–9 membrane attack complex of the complement system (41).
Perforin pores are used to facilitate transport of granulysin and
granzyme into the target cell cytoplasm. Additionally, perforin
may serve other cytolytic functions in the target cell after the
transport of cytolytic molecules (42). Granzymes are a family of
serine proteases withmanymembers, themajor constituent inNK
cells being Granzyme B. This enzyme can initiate apoptosis of the
target cell through direct activation of Caspases 3 and 7 or through
proteolysis of the protein Bid. Cleavage of Bid allows the active
fragment to move to the mitochondrial membrane and form a
pore complexwith Bax andBak, promoting the exit of cytochrome
c into the cytosol, thereby initiating the formation of the caspase-
activating complex (43). Granzyme B can also mediate nuclear
destruction in the presence of perforin, and other granzymes
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may be able to mediate caspase-independent cell death pathways
(42). Although granzymes can be taken into target cells without
perforin, full effects of these enzymes are not observed unless
perforin is present (42).
Granulysin shares homology with a family of proteins called
saposins, acid sphingomyelinase, and several Amoebapore pro-
teins from E. histolytica. These proteins all have the ability to inter-
act with lipids. Two isoforms of granulysin exist in NK cells, a 15-
kDa form that is constitutively secreted and a 9-kDa form found
in cytolytic granules (44). Granulysin is broadly antimicrobial and
tumoricidal. Able to kill extracellularM. tb on its own, granulysin
is not effective against intracellular M. tb without the presence
of perforin in which case it is highly effective at disrupting lipid
metabolism and oxidative phosphorylation (44, 45). Damage to
lipid membranes leads to release of cytochrome c into the cytosol
initiating apoptosis along with generating reactive oxygen species
(ROS) (46).
Fas (APO-1/CD95) is a TNF receptor family trans-membrane
death receptor responsible for cell lysis, whose ligand (FasL) is
expressed in NK cells (37, 47). The Fas receptor can be found
on most cell types in the body, and is of particular interest in
the context of macrophage expression. Upon FasL–Fas ligation
a death-inducing signaling complex (DISC) forms, composed of
multiple proteins, including Fas, Fas-associated death domain
(FADD), and caspase-8. Activation of caspase-8 by DISC initiates
the extra-mitochondrial apoptotic pathway (47). Macrophages
infected withM. tb undergo NK-mediated apoptosis through this
Fas pathway, to limit viability ofM. tb (48).
Natural killer cells express CD40L, the ligand for CD40 that
is expressed on antigen presenting cells and macrophages. (38,
39). Engagement of CD40 is central to the initiation of the
immune response. After ligation, CD40 leads to up-regulation
of co-stimulatory molecules CD80 and CD86 on the cell surface
of macrophages as well as generation of nitric oxide (NO) when
accompanied by IFN-γ (49). HIV infection demonstrates a sig-
nificant relationship between CD40 expression and immunity to
opportunistic pathogens. Candida albicans, cytomegalovirus, and
Toxoplasma gondii infection concomitant with HIV results in cells
with impaired CD40 expression and function (40). With exposure
to T. gondii, cells from HIV-infected patients have decreased
production of IL-12 and IFN-γ that can be partially restored with
recombinant CD40. This effect on CD40 most likely contributes
to the increased susceptibility of HIV-infected patients to oppor-
tunistic pathogens, by diminishing the activity of cell-mediated
immune responses (40).
Natural killer cell production of IFN-γ andTNF-α increases the
cytolytic ability of the NK cell by up-regulating ICAM-1 adhesion
molecules in target cells through activation of the NF-κB pathway
(50). ICAM-1 expression allows for greater target cell adhesion to
NK cells, increasing cytolysis.
Indirect Mechanisms of NK Cells and
IFN-γ-Induced Effector Mechanisms in
Macrophages
Interferon gamma released by NK cells can trigger numerous
intracellular effector mechanisms within macrophages, such as
FIGURE 1 | NK cells inhibit M. tb growth via IFN-γ , TNF-α , Perforin and
Granulysin, and Granzyme.
activation of NADPH-oxidase type 1 and 2 (NOX1, 2) as well as
NO synthase type 2 (NOS2), leading to formation of ROS and
reactive nitrogen species (RNS), respectively (51, 52) (Figure 1).
NOS2 expression in humans has been controversial but recent
studies have demonstrated the expression of this isoform after
immune cell activation (53–55). IFN-γ also up-regulates the
expression of IgG Fc receptor FcγRI in monocytes to increase
opsonization dependent phagocytosis (51).
NOX2 is recruited to phagosomes by IFN-γ stimulation where





NADPH (56, 57). NOS2 catalyzes the conversion of -arginine
and O2 into NO and citrulline (58). TNF-α released by NK
cells also contributes to macrophage mitochondrial ROS forma-
tion through TNF receptor 1 (TNFR1) complex association with
NOX1, induction of NOX2, and through a receptor-interacting
serine-threonine kinases 1 and 3 (RIP1-RIP3)-dependent path-
way, which can lead to programed necrosis (59–61).
Superoxide can spontaneously generate hydrogen peroxide and
hydroxyl radicals (56, 57). ROS and RNS can react further with
each other to generate NO2 and peroxynitrite (OONO ) (56,
62, 63). These various reactive species contribute antimicrobial
oxidative destruction to membrane lipids and proteins, DNA, and
enzymes (56).
Nitrosoglutathione (GSNO) is more
Potent than NO Alone
Although an unquestionably powerful antimicrobial agent,
the limitations of NO are clear. A short half-life limits its
potent antimicrobial properties while protecting our cells from
widespread, uncontrolled destruction. As it turns out, human
cells have evolved a particularly useful method of keeping NO in
reserve for immediate, long-lasting effects with a slow-release. In
a process known as S-nitrosylation, NO reacts with the tripeptide
antioxidant glutathione (GSH) to form S-nitrosoGSH (GSNO).
GSNO acts as a donor of NO, releasing it to the cell as needed.
In the form of GSNO, NO can better spread throughout the
system, being readily transported to other parts of the body.
Thismechanism proves particularly powerful during an infection,
where macrophage activation utilizes massive quantities of NO.
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The superior functions of GSNO are well evidenced, with studies
indicating a cidal effect of GSNO on M. tb by means of its “as-
needed” release of NO. GSNO has also been found to protect
against oxidative stress caused by peroxynitrite in brain, as well
as oxidative stress-induced apoptosis through induction of C-
GMP-mediated synthesis of thioredoxin. Both the destructive and
protective functions of GSNO represent a more potent and stable
mechanism through which the cell can utilize the powerful effects
of NO in the immune system. GSNO has therefore been shown
to play a major role in macrophage function in controlling M. tb
growth (63, 64).
Natural Killer Cells in M. tb and
HIV Infection
Natural killer cells isolated from healthy donors have been shown
to lyse infected monocytes and reduce the rate of intracellular
M. tb growth (22, 25). Depletion of NK cells in a murine model
enhances the growth of M. avium (21). However, one study has
revealed that though NK cells are expanded in C57BL/6 mice in
response to M. tb infection, there is no increase in bacterial load
when NK cells were depleted, suggesting that there is redundancy
in the cellular response to mycobacterial infection (15). Interest-
ingly, in T-cell deficient mice infected with M. tb, NK cells are
required for mycobacterial resistance, suggesting an important
role for NK cells in combating M. tb in immunocompromised
individuals (17).
Growth inhibition ofmycobacteria is, in part,mediated by solu-
ble factors, including IFN-γ andTNF-α produced byNKcells, and
through monocyte apoptosis induced by NK cell contact (23, 24).
NK cells are capable of destroyingM. tb via the cytolytic proteins
granulysin and perforin, in a contact-dependent manner without
the help of accessory cells, such as monocytes (27) (Figure 1).
In addition to early innate immune functions, NK cells are
found in mature granulomatous lesions in the lungs of M. tb
infected patients (18). Direct interactions between NK cells and
M. tb that emerge from granulomas after cell lysis can initiate
antimicrobial mechanisms, such as discharge of granulysin, with
static or cidal effects on the growth of M. tb (16, 18, 27). In the
presence of IL-2 and/or IL-12, NK cells express NKp44 leading
to direct interactions with the corresponding ligand on the cell-
surface of M. tb infected macrophages, triggering IFN-γ produc-
tion and increased macrophage activation (16, 18). Exposure of
NK cells toM. tb up-regulates the expression of NKG2D as well as
NKp30,NKp44, andNKp46,which then increase the expression of
granulysin and perforin through the MAP kinase signaling path-
way (27). After M. tb challenge, NK cells up-regulate nanotube-
like structures that tether mycobacteria, and redistribute perforin
vesicles toward these tethered regions (27).
FasL-induced apoptosis of M. tb infected macrophages leads
to greatly reduced viability of intracellular M. tb (48) (Figure 4).
HIV is able to de-regulate FasL and delay Fas-induced apoptosis of
infected peripheral blood lymphocytes leading to prolonged infec-
tion (36). This may contribute to increased viability of M. tb in
HIV-infected patients. NK cell cytolytic function has been shown
to be impaired in viremic HIV-1 infected subjects, potentially
contributing to the escape of infected CD4+ T cells from NK
cytotoxicity (65). This impairment is associated with an increased
surface expression of inhibitory receptors, such as LILRB1 and
NKG2A (31, 65, 66). Investigations also suggest surface expres-
sion of natural cytotoxicity receptors NKp46 may be elevated or
diminished, whereas NKp30 and NKp44 may be unchanged or
diminished in HIV-1 infected patients (66–68). Stimulation of
HIV-1 infected cultures with IL-15 and IL-12 has shown replen-
ishment of NK cell populations, which are selectively lost during
HIV infection (68).
HIV-1 infection has been shown to modulate the subsets of
IFN-γ producing NK cells in response to bacteria. A lower over-
all frequency of IFN-γ producing NK cells is seen from HIV-1
infected donors responding to E. coli and S. typhimurium, than
NK cells from uninfected donors (69). The decrease in bacte-
ria reactive, IFN-γ producing NK cells in HIV-1 infected sub-
jects contributes to the compromised innate immune response to
opportunistic infections.
The Role of Glutathione in the
NK Immune Response
Low levels of intracellular GSH dramatically decrease NK cell
cytotoxic functions (4, 26, 70). GSH is the main non-protein thiol
responsible for cellular homeostasis and oxidative balance (71).
GSH exists in oxidized (GSSG) and reduced/free form (rGSH),
with rGSH exhibiting antioxidant activity. Glutathione peroxi-
dase (GPx) detoxifies hydrogen peroxide, a potent source of ROS
within the cell, through a redox reaction with GSH (71, 72). rGSH
can be reclaimed from GSSG by the activity of glutathione reduc-
tase (GSR) (Figure 2). Treatment with N-acetyl cysteine (NAC)
results in increased intracellular GSH and treatment with buthio-
nine sulfoximine (BSO) decreases GSH. Although the uptake of
cysteine is considered as the rate-limiting step for the synthesis of
GSH, the most efficient way to increase the levels of cysteine in
cells is to supplement with NAC, which is easily taken up by the
cells and is non-toxic (72). BSO specifically inhibits the activity
of glutamate–cysteine ligase, the enzyme that catalyzes the first
reaction in the synthesis of GSH thereby inhibiting its synthesis
(Figure 2).
Notably, mycobacteria do not synthesize GSH and instead pro-
duce mycothiol to serve the same function. The exogenous nature
of GSH to mycobacteria may contribute to observations that the
virulent laboratory M. tb strain H37Rv is sensitive to GSH at
physiologic concentrations in vitro, supporting the bacteriostatic
nature of GSH (63, 70). Functionally the bacteriostatic activity of
GSH likely stems from the redox imbalances of the bacterium’s
metabolic homeostasis, which is normally regulated by the activ-
ity of mycothiol. Analysis of GSH’s inhibition of intracellular
H37Rv within human monocyte-derived macrophages (HMDM)
demonstrates the relationship between increased GSH and con-
trol of intracellular M. tb growth (10, 12, 13, 70, 73). Another
proposed mechanism for the anti-mycobacterial nature of GSH is
the significant structural similarities between GSH and penicillin
antibiotics (74, 75). The above findings have led to the conceptual
framework for the inhibition of intracellular H37Rv growth in
HMDM by the direct anti-mycobacterial action of GSH (10, 12,
13, 70, 73).
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FIGURE 2 | (A) The first step in de novo GSH biosynthesis is the rate-limiting step. Glutamate and cysteine are covalently linked by the heterodimeric enzyme
glutamylcysteine ligase (GCL) to form γ-glutamylcysteine. Notably, cysteine’s sulfhydryl bond is the source of GSH’s antioxidant capacity. (B) GSH synthase (GSS)
catalyzes the second step in GSH biosynthesis by linking glycine and γ-glutamylcysteine to form GSH which functions as the substrate for GPx in reduction of H2O2.
(C) Oxidized GSH, in the form of GSSG, can be converted to free GSH by glutathione reductase (GSR), utilizing NADPH as a cofactor.
Given this role of GSH it was further postulated that treatment
of whole blood cultures with NAC would result in greater inhi-
bition of H37Rv growth through both direct anti-mycobacterial
effects and enhancement of NK cell activation. Whole blood cul-
tures and blood cultures depleted of CD56+ NKwere each treated
with NAC and subsequently infected with processed H37Rv (4).
Growth inhibition occurred in the presence of NK cells and
NAC, whereas growth continued at different rates in all other cell
cultures with NK cells or NAC alone.
The effects of GSH in enhancing the cytolytic activity of
NK cells are demonstrated through cytotoxicity assays. NK cell
cytolytic activity increases in the presence of NAC and fur-
ther increases with the addition of cytokines. Treatment with
NAC+IL-2+IL-12 exhibits the greatest cytolytic activity, com-
pared with any individual component alone. It can therefore be
concluded that GSH alone and with cytokines is an important
component affecting NK cell cytotoxicity (4).
Furthermore, the effects of NAC+ cytokines are important in
NK cell control of M. tb growth. Monocytes cultured in an envi-
ronment without NK cells display a fourfold increase in intracel-
lular growth of H37Rv, whereas monocytes co-cultured with NK
cells display only a threefold increase of H37Rv (10). Treatment
of NK cells with NAC results in additional growth inhibition
of H37Rv (only a twofold increase in the growth compared to
negative control). Treatment with IL-2+IL-12+NAC remarkably
leads to growth stasis of H37Rv, whereas IL-2+IL-12 alone does
not lead to such stasis, suggesting that NAC has a marked effect.
Further reinforcing the link between GSH and NK cell function,
NK cells grown with BSO which functionally blocks the GSH
pathway, result in a maximal fivefold increase in H37Rv intracel-
lular growth (10).
The above findings indicate that GSH controls M. tb infection
by its direct anti-mycobacterial effects as well as by activating NK
cells in conjunction with IL-2+IL-12 (Figure 3) (10, 13). Notably,
NK cell co-incubation with NAC and NAC+IL-2+IL-12 led to a
measured increase in CD40L and FasL (10). GSH, along with IL-
2+IL-12, clearly plays a role enhancing the ability of NK cells to
express cytotoxic ligands and, as such, serve asmarkers forNK cell
activation and regulate NK cell induction of apoptosis in targeted
cells (Figure 4C).
FasL and CD40L have an observable role in monocytes’ con-
trol of M. tb infection, demonstrated by studies that leveraged
neutralizing antibodies to block their functional role. Interest-
ingly, blocking CD40L results in abrogation of the static effect
of IL-2+IL-12+NAC on intracellular growth patterns of H37Rv,
resulting in a threefold increase of intracellular H37Rv growth
(10). Neutralization of FasL results in a fivefold increase in the
intracellular growth of H37Rv, whereas monocytes co-cultured
with untreated NK cells demonstrate a fourfold increase of intra-
cellular H37Rv. NK cells rely on proper FasL and CD40L func-
tioning and monocytes rely on Fas and CD40 functioning in
order to effectively inhibit the growth of intracellularM. tb. Taken
together, GSH has a significant and instrumental role in aug-
menting and enhancing NK cell functions, enhancing the abil-
ity of NK cells to limit intracellular infections inside monocytes
(Figures 4B,C) (10).
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FIGURE 3 | Impact of NK cells on the growth of M. tb in human
macrophages in the presence or absence of thiols and cytokines.
The graph summarizes data from different studies (10, 13). BSO inhibits the
synthesis of GSH, whereas NAC enhances the availability of rGSH.
FIGURE 4 | (A) Intracellular survival of M. tb inside human macrophages.
(B) Presence of NK cells reduces the intracellular survival of M. tb inside
human macrophages. (C) Increasing GSH in NK cells reduces the intracellular
survival of M. tb inside human macrophages by promoting interactions
between Fas–FasL and CD40–CD40L. (D) HIV infection decreases the levels
of GSH in NK cells leading to enhanced survival of M. tb inside human
macrophages.
GSH Levels in NK Cells from Healthy and
HIV-Infected Subjects
Human immunodeficiency virus-positive individuals tend to have
much lowerNK cell GSH concentrations in comparison to healthy
subjects. (10). Although HIV infects CD4 T cells and mono-
cytes, a significant decrease in the intracellular levels of GSH
in NK cells has been observed. This is due to elevated levels of
FIGURE 5 | HIV infection induced oxidative stress and redox
imbalance in leading to enhanced susceptibility to M. tb infection.
circulating TNF-α and ROI induced by HIV infection, which
require the anti-oxidative protection of GSH (12, 73). Decreased
GSH levels in NK cells from individuals with HIV infection is
accompanied by increased multiplication of M. tb inside mono-
cytes (Figure 4D).
A marked decrease in levels of GSH and rGSH was found in
isolatedmacrophages in individuals withHIV infection compared
to healthy subjects (12, 73). Even more interesting is the ratio of
rGSH to GSSG. In the macrophages of HIV-infected individuals,
total GSH was approximately 30% rGSH and 70% GSSG. How-
ever, the total GSH in macrophages from healthy subjects was
approximately 60% rGSH and 40% GSSG (12, 73). Furthermore,
the concentration of GSH in T-cells of HIV-positive individuals
was much lower versus T-cells from healthy individuals (13).
Diminished concentrations of GSH in macrophages, NK, and T
cells derived from individuals with HIV infection was directly
correlated to diminished control of intracellular M. tb infection
(10, 12, 13, 73).
Several factors are responsible for low GSH in HIV infection.
The levels of free radicals andpro-inflammatory cytokines, such as
IL-1, IL-17, andTNF-α, are elevated in the plasma ofHIV-positive
individuals versus healthy individuals, whereas gene expression
for enzymes responsible for de novo GSH synthesis are decreased
in HIV-infected individuals’ macrophages (9). Based on these
results, the excess production of pro-inflammatory cytokines in
HIV-positive subjects likely leads to a rise in free radical levels
(10, 12, 13, 73). This, in conjunction with diminished GSH syn-
thesis enzyme expression, leads to a net effect of rGSH depletion,
possibly contributing to diminished immunity in HIV-positive
individuals (Figure 5) (76).
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Summary
Natural killer cells help control M. tb growth through mul-
tiple mechanisms and play a particularly important role in
immune compromised individuals that lack the ability to
mount a sufficient T cell response. These mechanisms include
release of cytokines, such as IFN-γ and TNF-α, production
of cytolytic proteins, such as perforin and granulysin, and
direct interactions between CD40/CD40L and Fas/FasL on
the mycobacteria surface (10, 23, 27, 37). Recent studies
indicate that NK cells can be activated by IL-2, IL-12, and
GSH to control M. tb infections (10, 13). GSH also functions
to limit the intracellular growth of M. tb in human and
murine peripheral blood-derived monocytes, likely through
direct anti-mycobacterial activity, functioning as an effector
in innate defense and by activating immune cells (4, 10, 12,
13, 70, 73). NK cell function and intracellular GSH levels are
significantly compromised in HIV-infected individuals, which
is critical given the increased susceptibility of HIV-infected
individuals to M. tb infection, particularly disseminated
disease (4).
Upward trends in the global incidence of TB are largely the
result of the emergence of MDR and XDR M. tb strains and an
increasing number of immunocompromised individuals due to
the AIDS pandemic. These phenomena raise the likelihood that
drug-susceptible TB may eventually be replaced by largely drug-
resistant TB, thereby severely restricting treatment modalities.
As there have been no new drug therapies targeted at TB during
the past 40 years, immuno-adjunctive therapy holds a promising
role in potentially expanding treatment options and outcomes for
refractory M. tb infections. By exploring the role of NK cells in
HIV and TB infection, it is clear that immunotherapies enhancing
the function ofNK cells will play a role in treatment in conjunction
with anti-mycobacterial drugs. We anticipate that research in
the coming years will find a likely role for GSH as a highly
promising immune-adjunctive component of treatment protocols
for MDR-TB, particularly in immunocompromised individuals
suffering from HIV.
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